Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma

References

• Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35:943–951.
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranza R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-Allo study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012 ;97:310–317.
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation:a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671–3677.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Kayani, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971–978.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948–3955.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for haematological malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013;19:117–122.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013;119:978–985.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013;121: 849–857.
   PubMed Web of Science ®Google Scholar
• Peccatori J, Clerici D, Forcina A, et al. In-vivo T-regs generation by rapamycin-mycophenolate-ATG as a new platform for GVHD prophylaxis in T-cell repleted unmanipulated haploidentical peripheral stem cell transplantation: results in 59 patients. Bone Marrow Transplant 2010;45(Suppl. 2): Abstract 88.
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 2008 ;14:1279–1287.
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Furst S, et al. Lower relapse and better PFS among chemosensitive patients undergoing allogeneic transplantation by haploidentical compared with HLA-identical DONOR: results on a cohort of 94 patients with Hodgkin's lymphoma. Blood 2013;122(Suppl. 1): Abstract 2144.
   Google Scholar
• Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusion contribute to improve T-cell recovery. Blood 2009;113:4771–4779.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014;20:314–318.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu DH, Xu LP, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 2012;47:1099–1104.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117:3921–3928.
   PubMed Web of Science ®Google Scholar
• Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusion in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003;31:39–44.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Tichelli A, Meyer-Monard S. Purified donor NK-lymphocyte infusion to consolidate engrafment after haploidentical stem cell transplantation. Leukemia 2004;18:1935–1938.
   Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Donor lympocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007;92:414–417.
   PubMed Web of Science ®Google Scholar